Career scientists at the Food and Drug Administration completed comprehensive vaccine safety studies involving millions of patient records, saw their work accepted by peer-reviewed journals, then received orders from political appointees to withdraw the research before publication. The suppression of taxpayer-funded studies examining COVID-19 and shingles vaccine safety has sparked concern among medical professionals about the selective release of federal health data.

Peer-Reviewed Studies Pulled from Publication

In October 2025, FDA scientists were directed to withdraw two COVID-19 vaccine safety studies that had already been accepted by the journals Drug Safety and Vaccine. The larger study examined records of 7.5 million Medicare beneficiaries for 14 pre-specified adverse outcomes following 2023-2024 COVID-19 vaccination, using rigorous methodology with up to 90 days of follow-up. The analysis identified only one signal exceeding statistical significance: anaphylaxis occurring at roughly one per million Pfizer-BioNTech doses.

A second study analyzed 4.2 million recipients aged six months to 64 years for more than a dozen potential adverse outcomes. This research identified rare febrile-seizure and myocarditis signals that were already documented on vaccine labels. Combined, these studies represented nearly 12 million vaccination records showing serious adverse effects to be very rare.

The agency also blocked publication of Shingrix safety studies in February 2025, declining to approve abstracts for submission to a major drug-safety conference. These analyses confirmed the elevated but low Guillain-Barré syndrome risk that has appeared on the vaccine’s package insert for years.

Procedural Anomaly Raises Questions

The FDA’s stated objection—that authors “drew broad conclusions that were not supported by the underlying data”—describes what infectious disease experts characterize as standard peer review processes. Medical journal reviewers routinely request narrower language and revised discussion sections before publication. What experts say does not happen in functioning scientific systems is political appointees instructing staff scientists to withdraw accepted manuscripts.

Dr. Monica Gandhi, professor of medicine at the University of California, San Francisco, expressed concern about the decision: “The COVID-19 vaccine safety studies had been peer reviewed and would have been extremely important to be published for reassurance of the public of the safety of these vaccines.”

Dr. William Schaffner of Vanderbilt University Medical Center emphasized the importance of data transparency: “Both vaccines are in widespread use, not only here in the United States, but around the world. Having these data available so that professional people can look at them and make their own assessments when they see the data is very important.”

Selective Information Release Pattern

The suppression becomes more significant when examined alongside information the agency has chosen to release. In late November 2025, a memo from the same FDA center linked the deaths of 10 children to COVID-19 vaccination—a claim the agency has not substantiated with supporting evidence. That memo was released and received widespread media coverage.

This pattern suggests vaccine-critical claims have moved through the agency at lower evidentiary thresholds, while reassuring safety findings have been held to standards that peer-reviewed papers could not realistically meet. Medical professionals describe this selectivity as concerning for public health decision-making.

Broader Implications for Public Health Surveillance

The suppression extends beyond individual studies to affect how surveillance signals reach physicians and the public. The Centers for Disease Control and Prevention has lost approximately 25% of its workforce in the past year and operates under editorial directives for its weekly journal publications.

This operational environment faces testing with major public health challenges on the horizon. The FIFA World Cup opens across North America in June 2026, bringing 48 teams to 11 U.S. host cities with more than 6 million attendees over 39 days. The tournament coincides with a regional measles resurgence: over 9,000 confirmed cases in Mexico since February 2025, Canada’s loss of measles elimination status in November, and U.S. vaccination coverage below the 95% threshold required for population immunity.

Dr. Robert Glatter, attending physician at Lenox Hill Hospital, warned about the consequences of withholding safety data: “The public health implications of blocking such studies are serious… secrecy can backfire. People who are already distrustful may see suppression where officials see caution.”

Scientific Integrity Under Political Pressure

The withdrawal of peer-reviewed vaccine safety studies represents what experts describe as an unprecedented procedural anomaly in federal health agencies. Career scientists completed methodologically sound research involving millions of patient records, saw their work survive peer review, then watched political appointees block publication based on objections that mirror routine editorial feedback.

The selective release pattern—suppressing reassuring safety data while circulating unsubstantiated safety concerns—raises questions about how political considerations may be influencing the dissemination of taxpayer-funded research. As public health agencies face operational changes and workforce reductions, the transparency of federal health surveillance becomes increasingly critical for maintaining public trust and informed medical decision-making.

This article draws on reporting from The Guardian and Healthline.